Skip to main content
. Author manuscript; available in PMC: 2020 Jan 1.
Published in final edited form as: J Thromb Haemost. 2018 Dec 10;17(1):113–125. doi: 10.1111/jth.14330

Fig. 2: Effect of FXIII catalytic A2 subunit deficiency on CCl4-induced experimental hepatic fibrosis.

Fig. 2:

Wild-type and FXIII−/− mice were treated with CCl4 or vehicle for 6 weeks and hepatic fibrosis was assessed 3 days after the last injection. (A) Representative photomicrographs (4x virtual objective, 20x insert) of hepatic αSMA labeling. (C) Hepatic Col1a1 expression. (D) Representative photomicrographs (4x virtual objective) of hepatic PSR staining. (F) Representative photomicrographs (4x virtual objective) of hepatic collagen type I labeling. (B, E, G) Quantification of positive staining area. Data are presented as mean + SEM (n=5–12 mice per group). * p < 0.05 compared to vehicle-treated mice.